<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angela M Rose</style></author><author><style face="normal" font="default" size="100%">Francisco Pozo</style></author><author><style face="normal" font="default" size="100%">Iván Martínez-Baz</style></author><author><style face="normal" font="default" size="100%">Clara Mazagatos</style></author><author><style face="normal" font="default" size="100%">Nathalie Bossuyt</style></author><author><style face="normal" font="default" size="100%">John Paul Cauchi</style></author><author><style face="normal" font="default" size="100%">Petrović, Goranka</style></author><author><style face="normal" font="default" size="100%">Isabela I Loghin</style></author><author><style face="normal" font="default" size="100%">Roberta Vaikutyte</style></author><author><style face="normal" font="default" size="100%">Silke Buda</style></author><author><style face="normal" font="default" size="100%">Machado, Ausenda</style></author><author><style face="normal" font="default" size="100%">Róisín Duffy</style></author><author><style face="normal" font="default" size="100%">Beatrix Oroszi</style></author><author><style face="normal" font="default" size="100%">Howard, Jennifer</style></author><author><style face="normal" font="default" size="100%">Echeverria, Aitziber</style></author><author><style face="normal" font="default" size="100%">Cristina Andreu</style></author><author><style face="normal" font="default" size="100%">Cyril Barbezange</style></author><author><style face="normal" font="default" size="100%">Aušra Džiugytė</style></author><author><style face="normal" font="default" size="100%">Diana Nonković</style></author><author><style face="normal" font="default" size="100%">Popescu, Corneliu-Petru</style></author><author><style face="normal" font="default" size="100%">Fausta Majauskaite</style></author><author><style face="normal" font="default" size="100%">Kristin Tolksdorf</style></author><author><style face="normal" font="default" size="100%">Verónica Gomez</style></author><author><style face="normal" font="default" size="100%">Domegan, Lisa</style></author><author><style face="normal" font="default" size="100%">Judit Krisztina Horváth</style></author><author><style face="normal" font="default" size="100%">Jesús Castilla</style></author><author><style face="normal" font="default" size="100%">Miriam García</style></author><author><style face="normal" font="default" size="100%">Thomas Demuyser</style></author><author><style face="normal" font="default" size="100%">Maria-Louise Borg</style></author><author><style face="normal" font="default" size="100%">Irena Tabain</style></author><author><style face="normal" font="default" size="100%">Mihaela Lazar</style></author><author><style face="normal" font="default" size="100%">Ieva Kubiliute</style></author><author><style face="normal" font="default" size="100%">Ralf Dürrwald</style></author><author><style face="normal" font="default" size="100%">Raquel Guiomar</style></author><author><style face="normal" font="default" size="100%">O'Donnell, Joan</style></author><author><style face="normal" font="default" size="100%">Kristóf, Katalin</style></author><author><style face="normal" font="default" size="100%">Nathalie Nicolay</style></author><author><style face="normal" font="default" size="100%">Sabrina Bacci</style></author><author><style face="normal" font="default" size="100%">Kissling, Esther</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">VEBIS SARI VE network team</style></author><author><style face="normal" font="default" size="100%">Belgium SARI Surveillance Network (BelsariNet)</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.</style></title><secondary-title><style face="normal" font="default" size="100%">Influenza Other Respir Viruses</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style  face="normal" font="default" size="100%">hospitals</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza A Virus, H1N1 Subtype</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza A Virus, H3N2 Subtype</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza, Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia</style></keyword><keyword><style  face="normal" font="default" size="100%">Seasons</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccine Efficacy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Feb</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">18</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was &amp;gt;55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>